Drug Trial Radar · NCT00098306
Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects
Last checked: Nov 20, 2026Latest source record: Apr 27, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
601
Actual
Start
Nov 2004
Primary completion
Apr 2007
Study completion Apr 2011
Sponsor
- Lead sponsor
- ViiV HealthcareGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- Pfizer
- First posted
- Dec 7, 2004
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Maraviroc (UK-427,857), a selective and reversible CCR5 coreceptor antagonist, has been shown to be active in vitro against a wide range of clinical isolates (including those resistant to existing classes). In HIV-1 infected patients, maraviroc (UK-427,857) given as monotherapy for 10 days reduced HIV-1 viral load by up to 1.6 log, consistent with currently available agents. Safety and toleration have been studied in over 400 subjects for up to 28 days at 300 mg twice daily. No significant effects were seen on the QTc interval. The purpose of this study is to evaluate the antiretroviral activity of maraviroc (UK-427,857) in HIV infected, treatment experienced patients who are failing their current antiretroviral regimen and are infected with R5-tropic virus exclusively. This study will involve more than 100 centers from the US and Canada to achieve a total randomized subject population of 500 subjects. Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy \[OBT (3-6 drugs based on treatment history and resistance testing)\] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone. The study will enroll over approximately a 9 month period with 48 weeks of treatment. This may be extended for an additional year depending on the results at 48 weeks. Physical examinations will be performed at study entry, weeks 4, 8, 12, 16, 20, 24, 32, 40, and 48. Blood samples will also be taken at study entry, weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, and 48. Additionally, blood samples will be drawn twice, at least 30 minutes apart, at weeks 2 and 24 for maraviroc (UK-427,857) pharmacokinetic analysis. As part of this clinical study a blood sample will also be taken for non-anonymized pharmacogenetic analysis. Patients will undergo a 12-lead electrocardiogram at study entry, weeks 24 and 48.
Conditions
- HIV Infections
Interventions
Maraviroc (UK-427,857)Drug
Maraviroc was given either once or twice per day with the dose adjusted according to the optimized background therapy
Optimized Background TherapyDrug
Maraviroc was given either once or twice per day with the dose adjusted according to the optimized background therapy
Optimized Background TherapyDrug
Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy \[OBT (3-6 drugs based on treatment history and resistance testing)\] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.
PlaceboDrug
Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy \[OBT (3-6 drugs based on treatment history and resistance testing)\] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.
Optimized Background TherapyDrug
Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy \[OBT (3-6 drugs based on treatment history and resistance testing)\] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone. The study will enroll over approximately a 9 month period with 48 weeks of treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Log 10-transformed Human Immunodeficiency Virus Ribonucleic Acid (HIV-1 RNA) Levels at BaselineTime frame: Baseline
- Change From Baseline in Log 10-transformed HIV-1 RNA Levels at Week 24Time frame: Baseline and Week 24
- Change From Baseline in Log 10-transformed HIV-1 RNA Levels at Week 48Time frame: Baseline and Week 48
Locations
22 sites in 2 countries. Site status is shown where the registry gives one.
Pfizer Investigational Site
Sacramento, California
Pfizer Investigational Site
San Francisco, California
Pfizer Investigational Site
San Francisco, California
Pfizer Investigational Site
San Francisco, California
Pfizer Investigational Site
Auroa, Colorado
Pfizer Investigational Site
Aurora, Colorado
Pfizer Investigational Site
Washington D.C., District of Columbia
Pfizer Investigational Site
Tampa, Florida
Pfizer Investigational Site
Tampa, Florida
Pfizer Investigational Site
Vero Beach, Florida
Pfizer Investigational Site
Atlanta, Georgia
Pfizer Investigational Site
New Orleans, Louisiana
Pfizer Investigational Site
Santa Fe, New Mexico
Pfizer Investigational Site
New York, New York
Pfizer Investigational Site
Rochester, New York
Pfizer Investigational Site
The Bronx, New York
Pfizer Investigational Site
Cincinnati, Ohio
Pfizer Investigational Site
Portland, Oregon
Pfizer Investigational Site
Austin, Texas
Pfizer Investigational Site
Annandale, Virginia
Pfizer Investigational Site
Vancouver, British Columbia, Canada
Pfizer Investigational Site
Montreal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.